A role for PKR in hematologic malignancies

Journal of Cellular Physiology

Volumn 223, Issue 3, 2010, Pages 572-591

  Blalock, William L ^a   Bavelloni, Alberto ^b   Piazzi, Manuela ^a   Faenza, Irene ^a   Cocco, Lucio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; PROTEIN KINASE R; PROTEIN P53; STAT PROTEIN;

BONE MARROW DEPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; ARTICLE; BLOOD DISEASE; CHEMISTRY; CHROMOSOME ABERRATION; ENZYMOLOGY; METABOLISM;

CHROMOSOME ABERRATIONS; EIF-2 KINASE; ENZYME ACTIVATION; HEMATOLOGIC NEOPLASMS; HUMANS; SIGNAL TRANSDUCTION;

EID: 77951231756     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22092     Document Type: Review

References (215)

1. Abraham N, Jaramillo ML, Duncan PI,Methot N, Icely PL, Stojdl DF, Barber GN, Bell JC. 1998. The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia. Exp Cell Res 244:394-404.
2. Abraham N, Stojdl DF, Duncan PI, Methot N, Ishii T, Dube M, Vanderhyden BC, Atkins HL, Gray DA, McBurney MW, Koromilas AE, Brown EG, Sonenberg N, Bell JC. 1999. Characterization of transgenicmice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. J Biol Chem 274:5953-5962.
3. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. 2006a. Inflammation and cancer: How hot is the link? Biochem Pharmacol 72:1605-1621.
4. Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H. 2006b. TNF blockade: An inflammatory issue. Ernst Schering Res Found Workshop, 161-186.
5. Akasaka T, Balasas T, Russell LJ, Sugimoto KJ, Majid A, Walewska R, Karran EL, Brown DG, Cain K, Harder L, Gesk S, Martin-Subero JI, Atherton MG, Bruggemann M, Calasanz MJ, Davies T, Haas OA, Hagemeijer A, Kempski H, Lessard M, Lillington DM, Moore S, Nguyen-Khac F, Radford-Weiss I, Schoch C, Struski S, Talley P, Welham MJ, Worley H, Strefford JC, Harrison CJ, Siebert R, Dyer MJ. 2007. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 109:3451-3461.
6. Alisi A, Mele R, Spaziani A, Tavolaro S, Palescandolo E, Balsano C. 2005. Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells. J Cell Physiol 205:25-31.
7. Baltzis D, Pluquet O, Papadakis AI, Kazemi S, Qu LK, Koromilas AE. 2007. The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. J Biol Chem 282:31675-31687.
8. Bando Y, Onuki R, Katayama T,Manabe T, Kudo T, Taira K, Tohyama M. 2005. Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease. Neurochem Int 46:11-18.
9. Barre B, Perkins ND. 2007. A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J 26:4841-4855.
10. Basu S, Panayiotidis P, Hart SM, He LZ, Man A, Hoffbrand AV, Ganeshaguru K. 1997. Role of double-stranded RNA-activated protein kinase in human hematological malignancies. Cancer Res 57:943-947.
11. Bennett RL, Blalock WL, Abtahi DM, Pan Y, Moyer SA, May WS. 2006. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood 108:821-829.
12. Beretta L, Gabbay M, Berger R, Hanash SM, Sonenberg N. 1996. Expression of the protein kinase PKR is modulated by IRF-1 and is reduced in 5q- associated leukemias. Oncogene 12:1593-1596.
13. Berlanga JJ, Santoyo J, De Haro C. 1999. Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2alpha kinase. Eur J Biochem 265:754-762.
14. Bing Z, Huang JH, Liao WSL. 2000. NFκB interacts with serum amyloid A3 enhancer factor to synergistically activate mouse serum amyloid A3 gene transcription. J Biol Chem 275:31616-31623.
15. Blalock WL, Grimaldi C, Fala F, Follo M, Horn S, Basecke J,Martinelli G, Cocco L, Martelli AM. 2009. PKR activity is required for acute leukemic cell maintenance and growth: A role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. J Cell Physiol 221:232-241.
16. Bonnet MC, Weil R, Dam E, Hovanessian AG, Meurs EF. 2000. PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex. Mol Cell Biol 20:4532-4542.
17. Bonnet MC, Daurat C, Ottone C, Meurs EF. 2006. The N-terminus of PKR is responsible for the activation of the NF-kappaB signaling pathway by interactingwith the IKKcomplex. Cell Signal 18:1865-1875.
18. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, Kiladjian JJ, Ribrag V, Fenaux P, Kroemer G. 2006. NF-kappaB constitutes a potential therapeutic target in highrisk myelodysplastic syndrome. Blood 107:1156-1165.
19. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BB. 2004. Expression of constitutively active nuclearkappa B Rel A transcription factor in blasts of acute myeloid leukemia. Hum Pathol 35:246-253.
20. Calkhoven CF, Muller C, Leutz A. 2000. Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev 14:1920-1932. (Pubitemid 30639525)
21. Carpick BW, Graziano V, Schneider D, Maitra RK, Lee X, Williams BR. 1997. Characterization of the solution complex between the interferon-induced, double-stranded RNA-activated protein kinase and HIV-I trans-activating region RNA. J Biol Chem 272:9510-9516. (Pubitemid 27154968)
22. Carvalho G, Fabre C, Braun T, Grosjean J, Ades L, Agou F, Tasdemir E, Boehrer S, Israel A, Veron M, Fenaux P, Kroemer G. 2007. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26:2299-2307.
23. Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D. 2007. High levels of the BCR/ABL oncoprotein are required for the MAPK-hn RNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 110:994-1003.
24. Chapiro E, Russell L, Radford-Weiss I, Bastard C, Lessard M, Struski S,Cave H, Fert-Ferrer S, Barin C, Maarek O, Della-Valle V, Strefford JC, Berger R, Harrison CJ, Bernard OA, Nguyen-Khac F. 2006. Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood 108:3560-3563.
25. Chen JJ. 2007. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: Relevance to anemias. Blood 109:2693-2699. (Pubitemid 46482060)
26. Chen H, Yang S, Yang Z, Ma L, Jiang D, Mao J, Jiao B, Cai Z. 2007. Inhibition of GSK-3beta decreases NF-kappaB-dependent gene expression and impairs the rat liver regeneration. J Cell Biochem 102:1281-1289. (Pubitemid 350220048)
27. Coffer PJ, Koenderman L, de Groot RP. 2000. The role of STATs in myeloid differentiation and leukemia. Oncogene 19:2511-2522. (Pubitemid 30339207)
28. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. 2007. Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat Rev Cancer 7:118-129. (Pubitemid 46164747)
29. Cuddihy AR, Wong AH, Tam NW, Li S, Koromilas AE. 1999. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 18:2690-2702.
30. Daher A, Laraki G, Singh M, Melendez-Pena CE, Bannwarth S, Peters AH, Meurs EF, Braun RE, Patel RC, Gatignol A. 2009. TRBP control of PACT-induced phosphorylation of protein kinase R is reversed by stress. Mol Cell Biol 29:254-265.
31. Dan HC, Baldwin AS. 2008. Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol 180:7582-7589.
32. Dan HC, Adli M, Baldwin AS. 2007. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res 67:6263-6269. (Pubitemid 47037508)
33. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. 2008. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22:1490-1500.
34. D'Andrea AD, Grompe M. 2003. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3:23-34.
35. Das S, Ward SV, Tacke RS, Suske G, Samuel CE. 2006. Activation of the RNA-dependent protein kinase PKR promoter in the absence of interferon is dependent upon Sp proteins. J Biol Chem 281:3244-3253. (Pubitemid 43845936)
36. Deb A, Zamanian-Daryoush M, Xu Z, Kadereit S,Williams BR. 2001. Protein kinase PKR is required for platelet-derived growth factor signaling of c-fos gene expression via Erks and Stat3. EMBO J 20:2487-2496. (Pubitemid 32452867)
37. Delgado Andre N, De Lucca FL. 2007. Knockdown of PKR expression by RNAi reduces pulmonary metastatic potential of B16-F10 melanoma cells in mice: Possible role of NF-kappaB. Cancer Lett 258:118-125. (Pubitemid 47600497)
38. De Luca C, Roulston A, Koromilas A, Wainberg MA, Hiscott J. 1996. Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-kappaB/Rel pathway via enhanced IkappaBalpha degradation. J Virol 70:5183-5193. (Pubitemid 26240690)
39. Demarchi F, Bertoli C, Sandy P, Schneider C. 2003. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 278:39583-39590. (Pubitemid 37258323)
40. Deng J, Lu PD, Zhang Y, Scheuner D, Kaufman RJ, Sonenberg N, Harding HP, Ron D. 2004. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol 24:10161-10168.
41. Donze O,Deng J, Curran J, Sladek R, Picard D, Sonenberg N. 2004. The protein kinase PKR:A molecular clock that sequentially activates survival and death programs. EMBO J 23:564-571.
42. Einhorn S, Heyman M. 1993. Chromosome 9 short arm deletions in malignant diseases. Leuk Lymphoma 11:191-196.
43. Eley HL, McDonald PS, Russell ST, Tisdale MJ. 2009. Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition. Cancer Chemother Pharmacol 63:651-659.
44. Fabre C, Carvalho G, Tasdemir E, Braun T, Ades L, Grosjean J, Boehrer S, Metivier D, Souquere S, Pierron G, Fenaux P, Kroemer G. 2007. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26:4071-4083. (Pubitemid 46920171)
45. Fagerlie SR, Koretsky T, Torok-Storb B, Bagby GC. 2004. Impaired type I IFN-induced Jak/STAT signaling in FA-C cells and abnormal CD4+ Th cell subsets in Fancc-/- mice. J Immunol 173:3863-3870.
46. Farrar MA, Olson SH, Perlmutter RM. 2000. Coumermycin-induced dimerization of GyrB-containing fusion proteins. Methods Enzymol 327:421-429.
47. Fernandez J, Yaman I, Merrick WC, Koromilas A, Wek RC, Sood R, Hensold J, Hatzoglou M. 2002. Regulation of internal ribosome entry site-mediated translation by eukaryotic initiation factor-2alpha phosphorylation and translation of a small upstream open reading frame. J Biol Chem 277:2050-2058.
48. Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F, Papa V, Libra M, Martinelli G, Cocco L, Martelli AM. 2007. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 67:4287-4294.
49. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C,Martinelli G, Blalock WL, Cocco L, Martelli AM. 2008. PKR is activated in MDS patients and its subcellular localization depends on disease severity. Leukemia 22:2267-2269.
50. Franke TF. 2008. PI3K/Akt: Getting it right matters. Oncogene 27:6473-6488.
51. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. 2000. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164:2200-2206.
52. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Recher C. 2009. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23:1029-1038.
53. Garcia R, Jove R. 1998. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 5:79-85.
54. Garcia MA, Collado M, Munoz-Fontela C, Matheu A, Marcos-Villar L, Arroyo J, Esteban M, Serrano M, Rivas C. 2006a. Antiviral action of the tumor suppressor ARF. EMBO J 25:4284-4292.
55. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. 2006b. Impact of protein kinase PKR in cell biology: From antiviral to antiproliferative action. Microbiol Mol Biol Rev 70:1032-1060.
56. Geletu M, Balkhi MY, Peer Zada AA, Christopeit M, Pulikkan JA, Trivedi AK, Tenen DG, Behre G. 2007. Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9. Blood 110:3301-3309.
57. Gerlitz G, Jagus R, Elroy-Stein O. 2002. Phosphorylation of initiation factor-2 alpha is required for activation of internal translation initiation during cell differentiation. Eur J Biochem 269:2810-2819.
58. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C,Wilkens L, Heinsch M, Willems H, Aivado M, Aul C. 2004. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18:113-119.
59. Giannopoulou M, Dai C, Tan X, Wen X,Michalopoulos GK, Liu Y. 2008. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. Am J Pathol 173:30-41.
60. Gil J, Alcami J, Esteban M. 2000. Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex. Oncogene 19:1369-1378.
61. Gil J, Rullas J, Garcia MA, Alcami J, Esteban M. 2001. The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappaB activation. Oncogene 20:385-394.
62. Gil J, Garcia MA, Gomez-Puertas P, Guerra S, Rullas J, Nakano H, Alcami J, Esteban M. 2004. TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol 24:4502-4512.
63. Gong R, Ge Y, Chen S, Liang E, Esparza A, Sabo E, Yango A, Gohh R, Rifai A, Dworkin LD. 2008. Glycogen synthase kinase 3beta: A novel marker and modulator of inflammatory injury in chronic renal allograft disease. Am J Transplant 8:1852-1863.
64. Green WB, Slovak ML, Chen IM, Pallavicini M, Hecht JL, Willman CL. 1999. Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). Leukemia 13:1960-1971.
65. Gromkowski SH, Mama K, Yagi J, Sen R, Rath S. 1990. Double-stranded RNA and bacterial lipopolysaccharide enhance sensitivity to TNF-alpha-mediated cell death. Int Immunol 2:903-908.
66. Grosjean-Raillard J, Ades L, Boehrer S, Tailler M, Fabre C, Braun T, De Botton S, Israel A, Fenaux P, Kroemer G. 2008. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis 13:1148-1161.
67. Guipaud O, Deriano L, Salin H, Vallat L, Sabatier L, Merle-Beral H, Delic J. 2003. B-cell chronic lymphocytic leukaemia: A polymorphic family unified by genomic features. Lancet Oncol 4:505-514.
68. Gupta V, Huang X, Patel RC. 2003. The carboxy-terminal, M3 motifs of PACT and TRBP have opposite effects on PKR activity. Virology 315:283-291.
69. Gustin JA, Korgaonkar CK, Pincheira R, Li Q, Donner DB. 2006. Akt regulates basal and induced processing of NF-kappaB2 (p100) to p52. J Biol Chem 281:16473-16481.
70. Gutierrez A, Look AT. 2007. NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 12:411-413.
71. Haefner B. 2003. A model for NF-kappa B regulation by GSK-3 beta. Drug Discov Today 8:1062-1063.
72. Hamanaka RB, Bennett BS, Cullinan SB, Diehl JA. 2005. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol Biol Cell 16:5493-5501.
73. Haneline LS, Broxmeyer HE, Cooper S, Hangoc G, Carreau M, Buchwald M, Clapp DW.1998. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood 91:4092-4098.
74. Haus O. 2000. The genes of interferons and interferon-related factors: Localization and relationships with chromosome aberrations in cancer. Arch Immunol Ther Exp (Warsz) 48:95-100.
75. Hii SI, Hardy L, Crough T, Payne EJ, Grimmett K, Gill D, McMillan NA. 2004. Loss of PKR activity in chronic lymphocytic leukemia. Int J Cancer 109:329-335. (Pubitemid 38252759)
76. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, Akira S, Aburatani H, Maru Y. 2008. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10:1349-1355.
77. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. 2000. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86-90. (Pubitemid 30460216)
78. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. 2002. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100:3553-3560. (Pubitemid 35303923)
79. Huntly BJ, Bench A, Green AR. 2003. Double jeopardy from a single translocation: Deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 102:1160-1168. (Pubitemid 36988018)
80. Icely PL, Gros P, Bergeron JJ, Devault A, Afar DE, Bell JC. 1991. TIK, a novel serine/threonine kinase, is recognized by antibodies directed against phosphotyrosine. J Biol Chem 266:16073-16077. (Pubitemid 21907766)
81. Ishii T, Kwon H, Hiscott J, Mosialos G, Koromilas AE. 2001. Activation of the I kappa B alpha kinase (IKK) complex by double-stranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR. Oncogene 20:1900-1912. (Pubitemid 32458700)
82. Ito T, Warnken SP, May WS. 1999a. Protein synthesis inhibition by flavonoids: Roles of eukaryotic initiation factor 2alpha kinases. Biochem Biophys Res Commun 265:589-594.
83. Ito T, Yang M, May WS. 1999b. RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem 274:15427-15432. (Pubitemid 129518891) (Pubitemid 29254907)
84. Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, Chaturvedi MM, Aggarwal BB. 2007. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1- IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 26:1385-1397.
85. Janz M, Hummel M, Truss M, Wollert-Wulf B,Mathas S, Johrens K, Hagemeier C, Bommert K, Stein H, Dorken B, Bargou RC. 2006. Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 107:2536-2539.
86. Jeffrey IW, Kadereit S, Meurs EF, Metzger T, Bachmann M, Schwemmle M, Hovanessian AG, Clemens MJ. 1995. Nuclear localization of the interferon-inducible protein kinase PKR in human cells and transfected mouse cells. Exp Cell Res 218:17-27.
87. Johansson B, Fioretos T, Mitelman F. 2002. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76-94. (Pubitemid 34264171)
88. Kalb R, Neveling K, Nanda I, Schindler D, Hoehn H. 2006. Fanconi anemia: Causes and consequences of genetic instability. Genome Dyn 1:218-242.
89. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A. 2002. Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol 22:5962-5974. (Pubitemid 34815843)
90. Karehed K, Dimberg A, Dahl S, Nilsson K, Oberg F. 2007. IFN-gamma-induced upregulation of Fcgamma-receptor-I during activation of monocytic cells requires the PKR and NFkappaB pathways. Mol Immunol 44:615-624. (Pubitemid 44287039)
91. Kawakubo K, Kuhen KL, Vessey JW,George CX, Samuel CE. 1999. Alternative splice variants of the human PKR protein kinase possessing different 5'-untranslated regions: Expression in untreated and interferon-treated cells and translational activity. Virology 264:106-114. (Pubitemid 29531891)
92. Kazemi S, Mounir Z, Baltzis D, Raven JF, Wang S, Krishnamoorthy JL, Pluquet O, Pelletier J, Koromilas AE. 2007. A novel function of eIF2alpha kinases as inducers of the phosphoinositide-3 kinase signaling pathway. Mol Biol Cell 18:3635-3644.
93. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H. 2001.ADNAdamage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 7:283-292.
94. Kerr IM, Martin EM, Sonnabend JA,Metz DM. 1969. The mechanism of action of interferon: A comparison of ribosomes from interferon-treated and control cells. Biochem J 114:43P-44P.
95. Kim SH, Forman AP, Mathews MB, Gunnery S. 2000. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene 19:3086-3094. (Pubitemid 30438465)
96. Kim SH, Gunnery S, Choe JK, Mathews MB. 2002. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 21:8741-8748. (Pubitemid 36132395)
97. Kimball SR, Fabian JR, Pavitt GD, Hinnebusch AG, Jefferson LS. 1998. Regulation of guanine nucleotide exchange through phosphorylation of eukaryotic initiation factor eIF2alpha. Role of the alpha- and delta-subunits of eiF2b. J Biol Chem 273:12841-12845.
98. Kimball SR, Clemens MJ, Tilleray VJ, Wek RC, Horetsky RL, Jefferson LS. 2001. The double-stranded RNA-activated protein kinase PKR is dispensable for regulation of translation initiation in response to either calcium mobilization from the endoplasmic reticulum or essential amino acid starvation. Biochem Biophys Res Commun 280:293-300.
99. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. 2000. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14:399-402. (Pubitemid 30142862)
100. Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N. 1992. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 257:1685-1689.
101. Koromilas AE, Cantin C, Craig AW, Jagus R, Hiscott J, Sonenberg N. 1995. The interferon-inducible protein kinase PKR modulates the transcriptional activation of immunoglobulin kappa gene. J Biol Chem 270:25426-25434.
102. Korth MJ, Edelhoff S, Disteche CM, Katze MG. 1996. Chromosomal assignment of the gene encoding the human 58-kDa inhibitor (PRKRI) of the interferon-induced dsRNA-activated protein kinase to chromosome 13q32. Genomics 31:238-239. (Pubitemid 26044781)
103. Koschmieder S, D'Alo F, Radomska H, Schoneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Muller-Tidow C, Serve H, Tenen DG. 2007. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood 110:3695-3705.
104. Kota J, Caceres N, Constantinescu SN. 2008. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 22:1828-1840.
105. Krishnamoorthy T, Pavitt GD, Zhang F, Dever TE, Hinnebusch AG. 2001. Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation. Mol Cell Biol 21:5018-5030.
106. Kubica N, Jefferson LS, Kimball SR. 2006. Eukaryotic initiation factor 2B and its role in alterations in mRNA translation that occur under a number of pathophysiological and physiological conditions. Prog Nucleic Acid Res Mol Biol 81:271-296. (Pubitemid 44691675)
107. Kuhen KL, Samuel CE. 1999. Mechanism of interferon action: Functional characterization of positive and negative regulatory domains that modulate transcriptional activation of the human RNA-dependent protein kinase Pkr promoter. Virology 254:182-195.
108. Kumar A,Haque J, Lacoste J, Hiscott J, Williams BR. 1994. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci USA 91:6288-6292.
109. Kumar A, Yang YL, Flati V, Der S, Kadereit S, Deb A, Haque J, Reis L, Weissmann C, Williams BR. 1997. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: Role of IRF-1 and NF-kappa B. EMBO J 16:406-416.
110. Lechward K, Awotunde OS, Swiatek W, Muszynska G. 2001. Protein phosphatase 2A: Variety of forms and diversity of functions. Acta Biochim Pol 48:921-933.
111. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC. 2007. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130:440-455.
112. Lee YY, Cevallos RC, Jan E. 2009. An upstream open reading frame regulates translation of GADD34 during cellular stresses that induce eIF2alpha phosphorylation. J Biol Chem 284:6661-6673.
113. Lenardo MJ, Fan CM, Maniatis T, Baltimore D. 1989. The involvement of NF-kappaB in betainterferon gene regulation reveals its role as widely inducible mediator of signal transduction. Cell 57:287-294. (Pubitemid 19112367)
114. Li S, Koromilas AE. 2001. Dominant negative function by an alternatively spliced form of the interferon-inducible protein kinase PKR. J Biol Chem 276:13881-13890. (Pubitemid 37391768) (Pubitemid 33657412)
115. Libermann TA, Baltimore D. 1990. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327-2334. (Pubitemid 20138854) (Pubitemid 120004845)
116. Lin TS, Mahajan S, Frank DA. 2000. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19:2496-2504. (Pubitemid 30339205)
117. Lu J, O'Hara EB, Trieselmann BA, Romano PR, Dever TE. 1999. The interferon-induced double-stranded RNA-activated protein kinase PKR will phosphorylate serine, threonine, or tyrosine at residue 51 in eukaryotic initiation factor 2alpha. J Biol Chem 274:32198-32203. (Pubitemid 129503817) (Pubitemid 29522961)
118. Mamaghani S, Patel S, Hedley DW. 2009. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 9:132.
119. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L. 2007. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: From bench to bedside. Curr Med Chem 14:2009-2023.
120. Martin M, Rehani K, Jope RS, Michalek SM. 2005. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777-784. (Pubitemid 43090463)
121. McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH,Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM. 2007. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul 47:64-103.
122. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM. 2008. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22:708-722.
123. Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG. 1993. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 90:232-236.
124. Murad JM, Tone LG, de Souza LR, De Lucca FL. 2005. A point mutation in the RNA-binding domain I results in decrease of PKR activation in acute lymphoblastic leukemia. Blood Cells Mol Dis 34:1-5.
125. Nerlov C. 2004. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 4:394-400.
126. Nerlov C. 2007. The C/EBP family of transcription factors: A paradigm for interaction between gene expression and proliferation control. Trends Cell Biol 17:318-324.
127. Nika J, Rippel S, Hannig EM. 2001. Biochemical analysis of the eIF2beta gamma complex reveals a structural function for eIF2alpha in catalyzed nucleotide exchange. J Biol Chem 276:1051-1056.
128. Nussbaum JM, Major M, Gunnery S. 2003. Transcriptional upregulation of interferon-induced protein kinase, PKR, in breast cancer. Cancer Lett 196:207-216.
129. Nyakern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T, Piccaluga PP, Martinelli G, Cocco L, Martelli AM. 2006. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 20:230-238.
130. Onuki R, Bando Y, Suyama E, Katayama T, Kawasaki H, Baba T, Tohyama M, Taira K. 2004. An RNA-dependent protein kinase is involved in tunicamycin-induced apoptosis and Alzheimer's disease. EMBO J 23:959-968.
131. Ortega LG, McCotter MD, Henry GL, McCormack SJ, Thomis DC, Samuel CE. 1996. Mechanism of interferon action. Biochemical and genetic evidence for the intermolecular association of the RNA-dependent protein kinase PKR from human cells. Virology 215:31-39.
132. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. 2005. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65:2076-2081.
133. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. 2007. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 110:735-742.
134. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. 1999. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82-85.
135. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M,Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zuniga-Pflucker JC, Dominguez M, Ferrando AA. 2007. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13:1203-1210.
136. Pang Q, Fagerlie S, Christianson TA, Keeble W, Faulkner G, Diaz J, Rathbun RK, Bagby GC. 2000. The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors. Mol Cell Biol 20:4724-4735.
137. Pang Q, Keeble W,Diaz J, Christianson TA, Fagerlie S, Rathbun K, Faulkner GR,O'Dwyer M, Bagby GC, Jr. 2001. Role of double-stranded RNA-dependent protein kinase in mediating hypersensitivity of Fanconi anemia complementation group C cells to interferon gamma, tumor necrosis factor-alpha, and double-stranded RNA. Blood 97:1644-1652.
138. Paquet C, Bose A, Polivka M, Peoc'h K, Brouland JP, Keohane C, Hugon J, Gray F. 2009. Neuronal phosphorylated RNA-dependent protein kinase in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 168:190-198.
139. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn P. 2009. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8:245-252.
140. Patel RC, Sen GC. 1998. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J 17:4379-4390.
141. Patel RC, Stanton P, McMillan NM, Williams BR, Sen GC. 1995. The interferon-inducible double-stranded RNA-activated protein kinase self-associates in vitro and in vivo. Proc Natl Acad Sci USA 92:8283-8287.
142. Peel AL. 2004. PKR activation in neurodegenerative disease. J Neuropathol Exp Neurol 63:97-105.
143. Peel AL, Bredesen DE. 2003. Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice. Neurobiol Dis 14:52-62.
144. Peel AL, Rao RV, Cottrell BA, Hayden MR, Ellerby LM, Bredesen DE. 2001. Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Hum Mol Genet 10:1531-1538.
145. Perrotti D, Neviani P. 2008. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 27:159-168.
146. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B. 2002. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30:48-58.
147. Pervin S, Tran AH, Zekavati S, Fukuto JM, Singh R, Chaudhuri G. 2008. Increased susceptibility of breast cancer cells to stress mediated inhibition of protein synthesis. Cancer Res 68:4862-4874.
148. Pestka S. 1997. The interferon receptors. Semin Oncol 24:S9-18-S19-40.
149. Pluquet O, Qu LK, Baltzis D, Koromilas AE. 2005. Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and glycogen synthase kinase 3beta. Mol Cell Biol 25:9392-9405.
150. Proud CG. 2005. eIF2 and the control of cell physiology. Semin Cell Dev Biol 16:3-12.
151. Radomska HS, Basseres DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y, Sternberg DW, Lokker N, Giese NA, Bohlander SK, Schnittger S, Delmotte MH, Davis RJ, Small D, Hiddemann W, Gilliland DG, Tenen DG. 2006. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 203:371-381.
152. Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BR, Stark GR. 2000. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and - independent pathways. EMBO J 19:263-272.
153. Raveh T, Hovanessian AG, Meurs EF, Sonenberg N, Kimchi A. 1996. Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons. J Biol Chem 271:25479-25484.
154. Reuter TY, Medhurst AL, Waisfisz Q, Zhi Y, Herterich S, Hoehn H, Gross HJ, Joenje H, Hoatlin ME, Mathew CG, Huber PA. 2003. Yeast two-hybrid screens imply involvement of Fanconi anemia proteins in transcription regulation, cell signaling, oxidative metabolism, and cellular transport. Exp Cell Res 289:211-221.
155. Reuther JY, Reuther GW,Cortez D, Pendergast AM, Baldwin AS, Jr. 1998. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 12:968-981.
156. Roberts WK, Clemens MJ, Kerr IM. 1976a. Interferon-induced inhibition of protein synthesis in L-cell extracts: An ATP-dependent step in the activation of an inhibitor by doublestranded RNA. Proc Natl Acad Sci USA 73:3136-3140.
157. Roberts WK, Hovanessian A, Brown RE, Clemens MJ, Kerr IM. 1976b. Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature 264:477-480.
158. Romano PR, Garcia-Barrio MT, Zhang X, Wang Q, Taylor DR, Zhang F, Herring C,Mathews MB, Qin J, Hinnebusch AG. 1998. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. Mol Cell Biol 18:2282-2297.
159. Ruvolo VR, Kurinna SM, Karanjeet KB, Schuster TF, Martelli AM, McCubrey JA, Ruvolo PP. 2008. PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem 283:35474-35485.
160. Sadler AJ, Latchoumanin O, Hawkes D, Mak J, Williams BR. 2009. An antiviral response directed by PKR phosphorylation of the RNA helicase A. PLoS Pathog 5:e1000311.
161. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E, Xie D. 1997. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36:10117-10124.
162. Savinova O, Joshi B, Jagus R. 1999. Abnormal levels and minimal activity of the dsRNA-activated protein kinase, PKR, in breast carcinoma cells. Int J Biochem Cell Biol 31:175-189.
163. Schwabe RF, Brenner DA. 2002. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J PhysiolGastrointest Liver Physiol 283:G204-G211.
164. Shi Y, Vattem KM, Sood R, An J, Liang J, Stramm L, Wek RC. 1998. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol 18:7499-7509.
165. Shimizu N, Ohta M, Fujiwara C, Sagara J, Mochizuki N, Oda T, Utiyama H. 1991. Expression of a novel immediate early gene during 12-O- tetradecanoylphorbol-13-acetate-induced macrophagic differentiation of HL-60 cells. J Biol Chem 266:12157-12161.
166. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. 2002. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 277:3863-3869.
167. Sonenberg N. 2008. eIF4E, the mRNA cap-binding protein: From basic discovery to translational research. Biochem Cell Biol 86:178-183.
168. Spriggs KA, Bushell M, Mitchell SA, Willis AE. 2005. Internal ribosome entry segment-mediated translation during apoptosis: The role of IRES-trans-acting factors. Cell Death Differ 12:585-591.
169. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA. 2008a. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22:686-707.
170. Steelman LS, Stadelman KM, Chappell WH, Horn S, Basecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. 2008b. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12:1139-1165.
171. Steinbrecher KA, Wilson W III, Cogswell PC, Baldwin AS. 2005. Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol 25:8444-8455.
172. Sterneck E, Zhu S, Ramirez A, Jorcano JL, Smart RC. 2006. Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis. Oncogene 25:1272-1276.
173. Stoneley M, Willis AE. 2004. Cellular internal ribosome entry segments: Structures, transacting factors and regulation of gene expression. Oncogene 23:3200-3207.
174. Storlazzi CT, Albano F, Dencic-Fekete M, Djordjevic V, Rocchi M. 2007. Late-appearing pseudocentric fission event during chronic myeloid leukemia progression. Cancer Genet Cytogenet 174:61-67.
175. Stuhmer T, Bargou RC. 2006. Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies. Cell Cycle 5:39-42.
176. Su Q, Wang S, Baltzis D, Qu LK, Wong AH, Koromilas AE. 2006. Tyrosine phosphorylation acts as a molecular switch to full-scale activation of the eIF2alpha RNA-dependent protein kinase. Proc Natl Acad Sci USA 103:63-68.
177. Su Q, Wang S, Baltzis D, Qu LK, Raven JF, Li S, Wong AH, Koromilas AE. 2007. Interferons induce tyrosine phosphorylation of the eIF2alpha kinase PKR through activation of Jak1 and Tyk2. EMBO Rep 8:265-270.
178. Sudhakar A, Ramachandran A, Ghosh S, Hasnain SE, Kaufman RJ, Ramaiah KV. 2000. Phosphorylation of serine 51 in initiation factor 2 alpha (eIF2 alpha) promotes complex formation between eIF2 alpha(P) and eIF2B and causes inhibition in the guanine nucleotide exchange activity of eIF2B. Biochemistry 39:12929-12938.
179. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. 2004. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279:39541-39554.
180. Takada Y, Ichikawa H, Pataer A, Swisher S, Aggarwal BB. 2007. Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene 26:1201-1212.
181. Takizawa T, Tatematsu C, Watanabe M, Yoshida M, Nakajima K. 2000. Three leucine-rich sequences and the N-terminal region of double-stranded RNA-activated protein kinase (PKR) are responsible for its cytoplasmic localization. J Biochem 128:471-476.
182. Tanaka H, Samuel CE. 1994. Mechanism of interferon action: Structure of the mouse PKR gene encoding the interferon-inducible RNA-dependent protein kinase. Proc Natl Acad Sci USA 91:7995-7999.
183. Tanaka H, Samuel CE. 2000. Mouse interferon-inducible RNA-dependent protein kinase Pkr gene: Cloning and sequence of the 5'-flanking region and functional identification of the minimal inducible promoter. Gene 246:373-382.
184. Tertian G, Avalos MR, Leonard C, Lavergne JM, Misrahi M, Tchernia G. 1996. Additional translocation (9;12)(p13;q24).1 in newly diagnosed chronic myeloid leukemia: Complete cytogenetic remission after interferon therapy. Hematol Cell Ther 38:269-273.
185. van den Beucken T, Koritzinsky M, Wouters BG. 2006. Translational control of gene expression during hypoxia. Cancer Biol Ther 5:749-755.
186. van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, Koritzinsky M, Wouters BG. 2007. Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. Radiother Oncol 83:346-352.
187. van der Velden AW, Thomas AA. 1999. The role of the 5' untranslated region of an mRNA in translation regulation during development. Int J Biochem Cell Biol 31:87-106.
188. Vattem KM, Staschke KA, Wek RC. 2001. Mechanism of activation of the double-stranded-RNA-dependent protein kinase, PKR: Role of dimerization and cellular localization in the stimulation of PKR phosphorylation of eukaryotic initiation factor-2 (eIF2). Eur J Biochem 268:3674-3684.
189. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML, Kee BL, Ferrando A, Miele L, Aifantis I. 2007. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 13:70-77.
190. Visvanathan KV, Goodbourn S. 1989. Double-stranded RNA activates binding of NF-kappa B to an inducible element in the human beta-interferon promoter. EMBO J 8:1129-1138.
191. von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. 2007. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clin Cancer Res 13:6032-6039.
192. Wang X, Paulin FE, Campbell LE, Gomez E, O'Brien K, Morrice N, Proud CG. 2001. Eukaryotic initiation factor 2B: Identification of multiple phosphorylation sites in the epsilon-subunit and their functions in vivo. EMBO J 20:4349-4359.
193. Wang S, Raven JF, Baltzis D, Kazemi S, Brunet DV, Hatzoglou M, Tremblay ML, Koromilas AE. 2006. The catalytic activity of the eukaryotic initiation factor-2alpha kinase PKR is required to negatively regulate Stat1 and Stat3 via activation of the T-cell protein-tyrosine phosphatase. J Biol Chem 281:9439-9449.
194. Wang A, Arantes S, Yan L, Kiguchi K,McArthur MJ, Sahin A, Thames HD, Aldaz CM, Macleod MC. 2008. The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis. BMC Cancer 8:268.
195. Ward SV, Samuel CE. 2002. Regulation of the interferon-inducible PKR kinase gene: The KCS element is a constitutive promoter element that functions in concert with the interferon-stimulated response element. Virology 296:136-146.
196. Ward SV, Samuel CE. 2003. The PKR kinase promoter binds both Sp1 and Sp3, but only Sp3 functions as part of the interferon-inducible complex with ISGF-3 proteins. Virology 313:553-566.
197. Ward AC, Touw I, Yoshimura A. 2000. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95:19-29.
198. Wek RC, Jiang HY, Anthony TG. 2006. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34:7-11.
199. Westermarck J, Hahn WC.2008. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 14:152-160.
200. Williams BR. 1999. PKR; a sentinel kinase for cellular stress. Oncogene 18:6112-6120.
201. Willis AE. 1999. Translational control of growth factor and proto-oncogene expression. Int J Biochem Cell Biol 31:73-86.
202. Wilson W III, Baldwin AS. 2008. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 68:8156-8163.
203. Wong AH, Tam NW,Yang YL, Cuddihy AR, Li S, Kirchhoff S, Hauser H, Decker T, Koromilas AE. 1997. Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways. EMBO J 16:1291-1304.
204. Wu S, Kaufman RJ. 1997. A model for the double-stranded RNA (dsRNA)-dependent dimerization and activation of the dsRNA-activated protein kinase PKR. J Biol Chem 272:1291-1296.
205. Xu Z, Williams BR. 2000. The B56alpha regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR. Mol Cell Biol 20:5285-5299.
206. Yamaguchi K, Lee SH,Kim JS, Wimalasena J, Kitajima S, Baek SJ. 2006. Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res 66:2376-2384.
207. Yaman I, Fernandez J, Liu H, Caprara M, Komar AA, Koromilas AE, Zhou L, Snider MD, Scheuner D, Kaufman RJ, Hatzoglou M. 2003. The zipper model of translational control: A small upstream ORF is the switch that controls structural remodeling of an mRNA leader. Cell 113:519-531.
208. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A,Williams BR, Aguet M, Weissmann C. 1995. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 14:6095-6106.
209. Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, Chen CT, Kuo HP, Hsu JM, Sun HL, Chou CK, Buttar NS, Wang KK, Huang P, Ajani J, Hung MC. 2008. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett'sassociated esophageal adenocarcinoma. Cancer Res 68:2632-2640.
210. Zamanian-Daryoush M, Mogensen TH, Di Donato JA, Williams BR. 2000. NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol 20:1278-1290.
211. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. 1997. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94:569-574.
212. Zhang F, Romano PR, Nagamura-Inoue T, Tian B, Dever TE, Mathews MB, Ozato K, Hinnebusch AG. 2001. Binding of double-stranded RNA to protein kinase PKR is required for dimerization and promotes critical autophosphorylation events in the activation loop. J Biol Chem 276:24946-24958.
213. Zhang X, Li J, Sejas DP, Rathbun KR, Bagby GC, Pang Q. 2004. The Fanconi anemia proteins functionally interact with the protein kinase regulated by RNA (PKR). J Biol Chem 279:43910-43919.
214. Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. 2004. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood 103:1883-1890.
215. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC. 2002. CCAAT/enhancer binding proteinbeta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci USA 99:207-212.